Canada Health Alliance

“Is Curing Patients a Sustainable Business Model?” Goldman Sachs Analysts Ask

Beth Mole

One-shot cures for diseases are not great for business—more specifically, they’re bad for longterm profits—Goldman Sachs analysts noted in an April 10 report for biotech clients …

The investment banks’ report, titled “The Genome Revolution,” asks clients the touchy question: “Is curing patients a sustainable business model?” The answer may be “no,” according to follow-up information provided.

… To get around the sustainability issue overall, the report suggests that biotech companies focus on diseases or conditions that seem to be becoming more common and/or are already high-incidence. It also suggests that companies be innovative and constantly expanding their portfolio of treatments. This can “offset the declining revenue trajectory of prior assets.” Lastly, it hints that, as such cures come to fruition, they could open up more investment opportunities in treatments for “disease of aging.”

Latest articles

Dawn Lester & David Parker … As we have shown in many...
Dawn Lester & David Parker Modern medicine is widely acclaimed as being...
Dawn Lester & David Parker In parts one and two, we showed...
Dawn Lester & David Parker In the three previous parts of this...
Roger Koops For those who may not recall Chicken Little (AKA Henny...
Tristan Coleman Does the latest ‘climate consensus’ study show a genuine agreement...

Thank you!

Thank you for your membership application. As soon as your payment has been received your membership will be activated and you will be informed via email.

Thank you.

Thank you!

The form has been submitted successfully!